Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer

Oncotarget
Yun Gyoung KimWoo Chul Noh

Abstract

Although it has been proposed that the beneficial effect of HER2-targeted therapy in HER2-negative breast cancer is associated with the molecular subtype conversion, the underlying mechanism and the clinical biomarkers are unclear. Our study showed that breast cancer stem cells (BCSCs) mediated HER2 subtype conversion and radioresistance in HER2-negative breast cancer cells and evaluated serum HER2 as a clinical biomarker for HER2 subtype conversion. We found that the CD44+/CD24-/lowBCSCs from HER2-negative breast cancer MCF7 cells overexpressed HER2 and EGFR and showed the radioresistant phenotype. In addition, we showed that trastuzumab treatment sensitized the radioresistant phenotype of the CD44+/CD24-/lowcells with decreased levels of HER2 and EGFR, which suggested that HER2-targeted therapy in HER2-negative breast cancer could be useful for targeting BCSCs that overexpress HER2/EGFR. Importantly, our clinical data showed that serial serum HER2 measurement synchronously reflected the disease relapse and the change in tumor burden in some patients who were initially diagnosed as HER2-negative breast cancer, which indicated that serum HER2 could be a clinical biomarker for the evaluation of HER2 subtype conversion in patient...Continue Reading

References

Jun 18, 2003·Cancer Chemotherapy and Pharmacology·Shadan AliPhilip Agop Philip
Jul 13, 2004·Clinical Breast Cancer·Walter P CarneyChristopher P Price
Jul 20, 2004·The Journal of Pathology·Peter RegitnigSigurd F Lax
Oct 21, 2005·The New England Journal of Medicine·Harold J Burstein
Dec 22, 2005·Nature Reviews. Genetics·Andrew P FeinbergSteven Henikoff
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Feb 15, 2008·Breast Cancer Research and Treatment·Elyse E LowerStacy Harman
Feb 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marianne KyndiUNKNOWN Danish Breast Cancer Cooperative Group
Mar 28, 2008·The New England Journal of Medicine·Soonmyung PaikNorman Wolmark
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezRobert B Jenkins
Mar 8, 2011·The Lancet Oncology·Brian Leyland-Jones, Brian R Smith
Nov 30, 2011·Nature Reviews. Clinical Oncology·Carlos L ArteagaLuca Gianni
Apr 24, 2012·Biochimica Et Biophysica Acta·Lian LamHongtao Zhang
Jun 14, 2012·Clinical & Developmental Immunology·Appalaraju Jaggupilli, Eyad Elkord
Oct 24, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nadire DuruJian Jian Li
Jul 26, 2013·BMC Cancer·Marija BalicNadia Dandachi
Jun 13, 2015·SpringerPlus·Julia TchouHongtao Zhang
Sep 5, 2015·Cell Stem Cell·Michael D BrooksMax S Wicha

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
xenograft
FACS
PCR

Software Mentioned

ImageJ
IN Cell Analyzer
XLSTAT
Excel

Related Concepts

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Nadire DuruJian Jian Li
Cancer Control : Journal of the Moffitt Cancer Center
J Horton
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
R Nahta, Francisco J Esteva
© 2022 Meta ULC. All rights reserved